Mark Yarchoan

43PUBLICATIONS
261CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Experimental methods in fluid flow, heat and mass transfer
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Jul 16, 2026
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

|Jul 14, 2026
Quantitative calibration of a spatial QSP model identifies fibroblast impact on HCC immunotherapy.

|Jun 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

|Jun 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|Jun 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

|Jun 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Pageof 8

Frequent Collaborators

21 joint publications

Elizabeth M Jaffee

16 joint publications

Won Jin Ho

10 joint publications

Christopher Thoburn

10 joint publications

Marina Baretti